% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tichanek:275458,
      author       = {F. Tichanek and A. Försti$^*$ and A. Hemminki and O.
                      Hemminki and K. Hemminki$^*$},
      title        = {{S}urvival in melanoma in the nordic countries into the era
                      of targeted and immunological therapies.},
      journal      = {European journal of cancer},
      volume       = {186},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-00773},
      pages        = {133 - 141},
      year         = {2023},
      note         = {#LA:C020#},
      abstract     = {Survival in melanoma has been increasing and the most
                      recent interest is to observe the population-level impact of
                      novel targeted therapies and immunotherapy. We analysed
                      survival in melanoma from Denmark (DK), Finland (FI), Norway
                      (NO) and Sweden (SE) over a 50-years period
                      (1971-2020).Relative 1-5/1- and 5-year survival data were
                      obtained from the NORDCAN database for the years 1971-2020.
                      We estimated annual changes in survival rates and determined
                      significant breaking points for trends.Survival in melanoma
                      has reached the point where 1-year survival is approaching
                      $100\%$ (men $97.5-98.6\%,$ women $98.4-99.3\%,$ depending
                      on the country) and 5-year survival is $93\%$ for men
                      $(91.5-95.2\%)$ and $96\%$ for women $(95.3-97.2\%).$ The
                      highest survival figures were for DK. Significant increases
                      in both 1- and 5-year survival were observed in most
                      countries even towards the end of the follow-up (from 2006
                      to 2010-2011-2015 and further to 2016-2020).The main
                      increase in melanoma survival took place up to year 1990,
                      which was probably largely achieved through successful
                      population campaigns for sun protection and programmes for
                      early detection of lesions. Survival increased again after
                      year 2000 up to the last period 2016-2020. This late
                      development coincided with the introduction of targeted
                      therapies using BRAF and BRAF/MEK inhibitors, and towards
                      the end of the time period availability of checkpoint
                      inhibitors. The success of melanoma treatment in DK was
                      mostly likely due to the efficient use of modern therapies
                      and to the centralised treatment for metastatic disease.},
      keywords     = {Conditional survival (Other) / Immunotherapy (Other) /
                      Relative survival (Other) / Sun protection (Other) /
                      Targeted therapy (Other)},
      cin          = {B062 / C020 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)C020-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37068406},
      doi          = {10.1016/j.ejca.2023.03.019},
      url          = {https://inrepo02.dkfz.de/record/275458},
}